Clinical trial · Observational
Swedish Ibrance Registries Insights (SIRI)
Palbociclib Treatment Patterns in Swedish Patients With Metastatic Breast Cancer - Swedish Ibrance Registries Insights (SIRI)
NCT04654208CI-TRIAL-00106911SIRIrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Neoplasm of Breast | Malignant Breast Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| palbociclib | Drug | Palbociclib | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- HR+/HER2- locally advanced or MBC in combination with an aromatase inhibitor (AI)
- description
- Group Description: patients with at least one filled prescription of palbociclib (ATC (anatomic therapeutic chemical classification system ) code: L01XE33)
- interventionNames
- Drug: palbociclib
- label
- HR+/HER2- locally advanced or MBC cancer in combination with fulvestrant
- description
- Group Description: patients with at least one filled prescription of palbociclib ATC (code: L01XE33)
- interventionNames
- Drug: palbociclib
Primary outcomes (1)
- measure
- Proportion of patients on treatment
- timeFrame
- 01 January 2017 until 30 September 2020
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33) 2. Age ≥18 years at index date Exclusion Criteria: There are no exclusion criteria
References
Publications (0)
Data not yet available
No reference posted for this study.